Commensal gut bacteria modulate phosphorylation-dependent PPARλ transcriptional activity in human intestinal epithelial cells

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Nepelska, Malgorzata ^a   De Wouters, Tomas ^a,b   Jacouton, Elsa ^a   Béguet Crespel, Fabienne ^a   Lapaque, Nicolas ^a   Doré, Joël ^a   Arulampalam, Velmurugesan ^c   Blottière, Hervé M ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ETH ZURICH   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; ANGIOPOIETIN RELATED PROTEIN 4; ANGPTL4 PROTEIN, HUMAN; BUTYRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLIN2 PROTEIN, HUMAN; PROPIONIC ACID DERIVATIVE;

ANAEROBIC BACTERIUM; CELL CULTURE TECHNIQUE; CELL LINE; CONDITIONED MEDIUM; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA; MAPK SIGNALING; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ANGIOPOIETIN-LIKE 4 PROTEIN; BACTERIA, ANAEROBIC; BUTYRATES; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; HUMANS; INTESTINAL MUCOSA; MAP KINASE SIGNALING SYSTEM; PERILIPIN-2; PHOSPHORYLATION; PPAR GAMMA; PROPIONATES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 85014765748     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43199     Document Type: Article

References (51)

1. Sekirov, I., Russell, S. L., Antunes, L. C. M., Finlay, B. B. Gut Microbiota in Health and Disease. Physiol. Rev. 90, 859-904 (2010).
2. Cerf-Bensussan, N., Gaboriau-Routhiau, V. The immune system and the gut microbiota: friends or foes Nat. Rev. Immunol. 10, 735-44 (2010).
3. Cummings, J. H. Microbial Digestion of Complex Carbohydrates in Man. Proc. Nutr. Soc. 43, 35-44 (1984).
4. Albert, M. J., Mathan, V. I., Baker, S. J. Vitamin B12 synthesis by human small intestinal bacteria. Nature 283, 781-782 (1980).
5. Bäckhed, F., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101, 15718-23 (2004).
6. Hooper, L. V., Midtvedt, T., Gordon, J. I. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr. 22, 283-307 (2002).
7. Kelly, D., Delday, M. I., Mulder, I. Microbes and microbial effector molecules in treatment of inflammatory disorders. Immunol. Rev. 245, 27-44 (2012).
8. Le Chatelier, E., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541-6 (2013).
9. Cani, P. D., Delzenne, N. M., Amar, J., Burcelin, R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol. Biol. (Paris). 56, 305-9 (2008).
10. Brestoff, J. R., Artis, D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14, 676-84 (2013).
11. Kjer-Nielsen, L., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717-23 (2012).
12. Sayin, S. I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225-35 (2013).
13. Dreyer, C., et al. Control of the peroxisomal -oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-87 (1992).
14. Fajas, L., et al. The organization, promoter analysis, expression of the human PPARgamma gene. J Biol Chem 272, 18779-89 (1997).
15. Dubuquoy, L., et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55, 1341-9 (2006).
16. Sarraf, P., et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol. Cell 3, 799-804 (1999).
17. Kelly, D., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARgamma and RelA. Nat. Immunol. 5, 104-12 (2004).
18. Backhed, F., Manchester, J. K., Semenkovich, C. F., Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104, 979-84 (2007).
19. Wada, K., Nakajima, A., Blumberg, R. S. and inflammatory bowel disease: a new therapeutic PPAR target for ulcerative colitis and Crohn's disease. 7, 329-31 (2001).
20. Sarraf, P., Mueller, E., Jones, D. Differentiation and reversal of malignant changes in colon cancer through PPAR. Nat. Med. 4, 1046-52 (1998).
21. Slattery, M. L., et al. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 17, 239-49 (2006).
22. Anghel, S. I., Wahli, W. Fat poetry: a kingdom for PPAR gamma. Cell Res. 17, 486-511 (2007).
23. Lakhdari, O., et al. Identification of NF- B Modulation Capabilities within Human Intestinal Commensal Bacteria. J. Biomed. Biotechnol. 2011, 282356 (2011).
24. Nepelska, M., et al. Butyrate Produced by Commensal Bacteria Potentiates Phorbol Esters Induced AP-1 Response in Human Intestinal Epithelial Cells. PLoS One 7, e52869 (2012).
25. Korecka, A., et al. ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G1025-37 (2013).
26. Donohoe, D. R., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517-26 (2011).
27. Alex, S., et al. Short chain fatty acids stimulate Angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating PPAR. Mol. Cell. Biol. 33, 1303-16 (2013).
28. Klinder, A., et al. Fecal water as a non-invasive biomarker in nutritional intervention: comparison of preparation methods and refinement of different endpoints. Nutr. Cancer 57, 158-67 (2007).
29. Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., Macfarlane, G. T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221-7 (1987).
30. Backhed, F., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101, 15718-23 (2004).
31. Are, A., et al. Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells. Proc. Natl. Acad. Sci. USA 105, 1943-8 (2008).
32. Burns, K. A., Vanden Heuvel, J. P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771, 952-60 (2007).
33. Jia, W., Li, H., Zhao, L., Nicholson, J. K. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 7, 123-9 (2008).
34. Blottière, H. M., de Vos, W. M., Ehrlich, S. D., Doré, J. Human intestinal metagenomics: state of the art and future. Curr. Opin. Microbiol. 16, 232-9 (2013).
35. Shao, D., Lazar, M. A. Modulating nuclear receptor function: may the phos be with you. J. Clin. Invest. 103, 1617-8 (1999).
36. Laleveé, S., Ferry, C., Rochette-Egly, C. Phosphorylation control of nuclear receptors. Methods Mol. Biol. 647, 251-66 (2010).
37. Adams, M., Reginato, M. J., Shao, D., Lazar, M. A., Chatterjee, V. K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128-32 (1997).
38. Zhang, B., et al. Insulin-and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferatoractivated receptor gamma. J. Biol. Chem. 271, 31771-4 (1996).
39. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-85 (1995).
40. Raingeaud, J., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270, 7420-6 (1995).
41. Aronsson, L., et al. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 5 (2010).
42. Desreumaux, P., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193, 827-38 (2001).
43. Su, C. G., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104, 383-9 (1999).
44. Adachi, M., et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55, 1104-13 (2006).
45. Annese, V., Rogai, F., Settesoldi, A., Bagnoli, S. PPAR in Inflammatory Bowel Disease. PPAR Res. 2012, 620839 (2012).
46. Andersen, V., et al. Polymorphisms in NF- B, PXR, LXR, PPAR and risk of inflammatory bowel disease. World J. Gastroenterol. 17, 197-206 (2011).
47. Scher, J. U., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2, e01202 (2013).
48. Kumar, P. S., et al. New bacterial species associated with chronic periodontitis. J. Dent. Res. 82, 338-44 (2003).
49. Pédron, T., et al. A Crypt-Specific Core Microbiota Resides in the Mouse Colon. mBio 3, 00116-12 (2012).
50. Hungate, R. E. THE ANAEROBIC. Growth (Lakeland) (1950).
51. Couvigny, B., et al. Commensal Streptococcus salivarius Modulates PPAR Transcriptional Activity in Human Intestinal Epithelial Cells. PLoS One 10, e0125371 (2015).